CAPITAL & REGIONAL PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50 GBX | +0.60% |
|
0.00% | -13.19% |
| Apr. 24 | Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results | CI |
| Apr. 22 | Capital & Regional picks Gerry Murphy as non-exec director | AN |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is one of the best yield companies with high dividend expectations.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company is highly valued given the cash flows generated by its activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Commercial REITs
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -13.19% | 136M | B- | ||
| -0.20% | 46.5B | B | ||
| -13.75% | 12.42B | A- | ||
| -22.69% | 11.06B | A- | ||
| -13.01% | 10.89B | A- | ||
| -5.43% | 7.5B | C+ | ||
| -6.66% | 6.56B | A- | ||
| -8.23% | 5.83B | C- | ||
| -7.60% | 5.73B | B+ | ||
| -7.00% | 4.7B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CAL Stock
- Ratings Capital & Regional plc
